Therefore, we undertook a study to comprehensively analyse the diversity of mechanisms that might contribute to the activation of the PI3K pathway in melanoma and to understand how that impacts on the type of PI3K pathway therapy that might best be used to treat melanoma. This evidence concerns the gene PIK3CA and melanoma.